Mallinckrodt public limited company (MNK)
(Delayed Data from NYSE)
$16.14 USD
+0.44 (2.80%)
Updated May 3, 2019 04:02 PM ET
After-Market: $16.14 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[MNK]
Reports for Purchase
Showing records 1 - 20 ( 105 total )
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Generic Drugs
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department